Haloperidol Injection

Haloperidol injection and haloperidol extended-release injection are used to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Haloperidol injection is also used to control motor tics (uncontrollable need to repeat certain body movements) and verbal tics (uncontrollable need to repeat sounds or words) in people who have Tourette's disorder (condition characterized by motor or verbal tics). Haloperidol is in a class of medications called conventional antipsychotics. It works by decreasing abnormal excitement in the brain.

Haloperidol injection comes as a solution to be injected into a muscle by a healthcare provider. Haloperidol injection is usually given as needed for agitation, motor tics, or verbal tics. If you still have symptoms after you receive your first dose, you may be given one or more additional doses. Haloperidol extended-release injection comes as a solution to be injected into a muscle by a healthcare provider. Haloperidol extended-release injection is usually given once every 4 weeks.

Haloperidol injection and haloperidol extended-release injection may help control your symptoms but will not cure your condition. Continue to keep appointments to receive haloperidol even if you feel well. Talk to your doctor if you do not feel like you are getting better during your treatment with haloperidol injection.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before receiving haloperidol injection or haloperidol extended-release injection,

• tell your doctor and pharmacist if you are allergic to haloperidol, any other medications, or any of the ingredients in haloperidol injection or haloperidol extended-release injection. Ask your pharmacist for a list of the ingredients.

• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: alprazolam (Xanax); amiodarone (Cordarone, Nexterone, Pacerone); anticoagulants (blood thinners); antifungals medications such as itraconazole (Onmel, Sporanox) and ketoconazole (Nizoral); antihistamines (in cough and cold medications); medications for anxiety, depression, irritable bowel disease, mental illness, motion sickness, Parkinson's disease, seizures, ulcers, or urinary problems; buspirone; carbamazepine (Carbatrol, Tegretol, Teril, others); chlorpromazine; disopyramide (Norpace); diuretics ('water pills'); epinephrine (Adrenalin, Epipen, Twinject, others); erythromycin (E.E.S., E-Mycin, Erythrocin); fluoxetine (Prozac, Sarafem, Selfemra); fluvoxamine (Luvox); lithium (Lithobid); moxifloxacin (Avelox); narcotic medications for pain; nefazodone; paroxetine (Brisdelle, Paxil, Pexeva); promethazine (Promethegan); quinidine (in Nuedexta); rifampin (Rifadin, Rimactane, in Rifamate, in Rifater); sedatives; sertraline (Zoloft); sleeping pills; tranquilizers; and venlafaxine (Effexor XR). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with haloperidol, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

• tell your doctor if you have Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance). Your doctor will probably tell you not to receive haloperidol injection.

• tell your doctor if you have a low number of white blood cells. Also tell your doctor if you have or have ever had QT prolongation (an irregular heart rhythm that can lead to fainting, loss of consciousness, seizures, or sudden death); bipolar disorder (condition that causes episodes of depression, episodes of mania, and other abnormal moods); trouble keeping your balance; an abnormal electroencephalogram (EEG; a test that records electrical activity in the brain); seizures; an irregular heartbeat; low levels of potassium or magnesium in your blood; or heart or thyroid disease.

• tell your doctor if you are pregnant, especially if you are in the last few months of your pregnancy, or if you plan to become pregnant or are breastfeeding. If you become pregnant while receiving haloperidol, call your doctor. Haloperidol may cause problems in newborns following delivery if it is given during the last months of pregnancy.

• if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving haloperidol injection.

• you should know that receiving haloperidol injection or haloperidol extended-release injection may make you drowsy and may affect your ability to think clearly, make decisions, and react quickly. Do not drive a car or operate machinery after you receive haloperidol injection or haloperidol extended-release injection until you know how this medication affects you.

• you should know that alcohol can add to the drowsiness caused by this medication. Do not drink alcohol during your treatment with haloperidol.

• you should know that haloperidol injection may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

Unless your doctor tells you otherwise, continue your normal diet.

If you forget to keep an appointment to receive haloperidol extended-release injection, call your doctor to schedule another appointment as soon as possible.

• Haloperidol injection or haloperidol extended-release injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

  • mood changes

  • difficulty falling asleep or staying asleep

  • restlessness

  • anxiety

  • agitation

  • dizziness, feeling unsteady, or having trouble keeping your balance

  • headache

  • dry mouth

  • increased saliva

  • blurred vision

  • loss of appetite

  • constipation

  • diarrhea

  • heartburn

  • nausea

  • vomiting

  • breast enlargement or pain

  • breast milk production

  • missed menstrual periods

  • decreased sexual ability in men

  • increased sexual desire

  • difficulty urinating

• Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

  • fever

  • muscle stiffness

  • falling

  • confusion

  • fast or irregular heartbeat

  • sweating

  • decreased thirst

  • involuntary movements of tongue, face, mouth or jaw

  • uncontrollable eye movements

  • unusual, slowed, or uncontrollable movements of any part of the body

  • tightness in the throat

  • fine, worm-like tongue movements

  • neck cramps

  • difficulty breathing or swallowing

  • tongue that sticks out of the mouth

  • uncontrollable, rhythmic face, mouth, or jaw movements

  • difficulty walking

  • difficulty talking

  • seizures

  • seeing things or hearing voices that do not exist

  • yellowing of the skin or eyes

  • erection that lasts for hours

• Haloperidol injection or haloperidol extended-release injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

• If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

• unusual, slowed, or uncontrollable movements of any part of the body

• uncontrollable shaking of a part of the body

• stiff or weak muscles

• sedation

Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to haloperidol injection or haloperidol extended-release injection.

Ask your pharmacist any questions you have about haloperidol injection or haloperidol extended-release injection.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug	Interaction
Moxifloxacin	Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Haloperidol.
Repaglinide	Repaglinide The serum concentration of Repaglinide can be increased when it is combined with Haloperidol.
Montelukast	Montelukast The serum concentration of Haloperidol can be increased when it is combined with Montelukast.
Insulin Glargine (rDNA origin) Injection	Insulin Glargine (rDNA origin) Injection The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Haloperidol.
Leflunomide	Leflunomide The serum concentration of Haloperidol can be decreased when it is combined with Leflunomide.
Delavirdine	Delavirdine The serum concentration of Haloperidol can be increased when it is combined with Delavirdine.
Nevirapine	Nevirapine The serum concentration of Haloperidol can be increased when it is combined with Nevirapine.
Atorvastatin	Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Haloperidol.
Dolasetron	Dolasetron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dolasetron.
Aminophylline	Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Haloperidol.
Anagrelide	Anagrelide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Anagrelide.
Candesartan	Candesartan The metabolism of Haloperidol can be decreased when combined with Candesartan.
Cilostazol	Cilostazol The metabolism of Cilostazol can be decreased when combined with Haloperidol.
Clopidogrel	Clopidogrel The serum concentration of Haloperidol can be increased when it is combined with Clopidogrel.
Diphenoxylate	Diphenoxylate The risk or severity of CNS depression can be increased when Haloperidol is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole	Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Haloperidol.
Estrogen and Progestin (Oral Contraceptives)	Estrogen and Progestin (Oral Contraceptives) The serum concentration of Haloperidol can be increased when it is combined with Conjugated estrogens.
Fenofibrate	Fenofibrate The serum concentration of Haloperidol can be increased when it is combined with Fenofibrate.
Guanfacine	Guanfacine The risk or severity of CNS depression can be increased when Haloperidol is combined with Guanfacine.
Magnesium Hydroxide	Magnesium Hydroxide Haloperidol may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Methylergonovine	Methylergonovine The serum concentration of Haloperidol can be increased when it is combined with Methylergometrine.
Miglitol	Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Haloperidol.
Mycophenolate	Mycophenolate Haloperidol may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan	Naratriptan The risk or severity of CNS depression can be increased when Naratriptan is combined with Haloperidol.
Olsalazine	Olsalazine The therapeutic efficacy of Haloperidol can be increased when used in combination with Olsalazine.
Paregoric	Paregoric The risk or severity of CNS depression can be increased when Morphine is combined with Haloperidol.
Penbutolol	Penbutolol The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Acebutolol.
Pentazocine	Pentazocine The risk or severity of CNS depression can be increased when Haloperidol is combined with Pentazocine.
Potassium	Potassium Potassium may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone	Prednisone The serum concentration of Haloperidol can be increased when it is combined with Prednisone.
Ranitidine	Ranitidine The serum concentration of Ranitidine can be increased when it is combined with Haloperidol.
Reserpine	Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Haloperidol.
Rizatriptan	Rizatriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Rizatriptan.
Sumatriptan	Sumatriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Sumatriptan.
Tacrolimus	Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Haloperidol.
Tizanidine	Tizanidine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Tizanidine.
Triamcinolone	Triamcinolone The serum concentration of Haloperidol can be increased when it is combined with Triamcinolone.
Zolmitriptan	Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Haloperidol.
Ampicillin Injection	Ampicillin Injection Ampicillin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Doxycycline Injection	Doxycycline Injection The serum concentration of Haloperidol can be increased when it is combined with Doxycycline.
Famotidine Injection	Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Haloperidol.
Fluconazole Injection	Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Haloperidol.
Foscarnet Injection	Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Haloperidol.
Hydromorphone Injection	Hydromorphone Injection The risk or severity of CNS depression can be increased when Hydromorphone is combined with Haloperidol.
Interferon Beta-1b Injection	Interferon Beta-1b Injection The metabolism of Haloperidol can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection	Interferon Gamma-1b Injection The metabolism of Haloperidol can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection	Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Haloperidol.
Meperidine Injection	Meperidine Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Meperidine.
Methylprednisolone Injection	Methylprednisolone Injection The serum concentration of Haloperidol can be increased when it is combined with Methylprednisolone.
Metoclopramide Injection	Metoclopramide Injection The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.
Metronidazole Injection	Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Haloperidol.
Morphine Injection	Morphine Injection The risk or severity of CNS depression can be increased when Morphine is combined with Haloperidol.
Pamidronate Injection	Pamidronate Injection Pamidronic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Vancomycin Injection	Vancomycin Injection Haloperidol may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Zidovudine Injection	Zidovudine Injection The serum concentration of Haloperidol can be increased when it is combined with Zidovudine.
Altretamine	Altretamine The therapeutic efficacy of Amphetamine can be decreased when used in combination with Haloperidol.
Cefuroxime	Cefuroxime Cefuroxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cyclosporine	Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Haloperidol.
Ondansetron	Ondansetron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ondansetron.
Granisetron	Granisetron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Granisetron.
Torsemide	Torsemide The metabolism of Haloperidol can be decreased when combined with Torasemide.
Olanzapine	Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Haloperidol.
Alosetron	Alosetron The risk or severity of CNS depression can be increased when Alosetron is combined with Haloperidol.
Dofetilide	Dofetilide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dofetilide.
Entacapone	Entacapone The risk or severity of CNS depression can be increased when Entacapone is combined with Haloperidol.
Hydroxychloroquine	Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Haloperidol.
Meloxicam	Meloxicam The serum concentration of Haloperidol can be increased when it is combined with Meloxicam.
Oxcarbazepine	Oxcarbazepine The risk or severity of CNS depression can be increased when Oxcarbazepine is combined with Haloperidol.
Pantoprazole	Pantoprazole The serum concentration of Haloperidol can be increased when it is combined with Pantoprazole.
Temozolomide	Temozolomide Haloperidol may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Zaleplon	Zaleplon The risk or severity of CNS depression can be increased when Haloperidol is combined with Zaleplon.
Anakinra	Anakinra The metabolism of Haloperidol can be increased when combined with Anakinra.
Desloratadine	Desloratadine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Desloratadine.
Linezolid	Linezolid The risk or severity of CNS depression can be increased when Linezolid is combined with Haloperidol.
Trimipramine	Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Haloperidol.
Etanercept Injection	Etanercept Injection The metabolism of Haloperidol can be increased when combined with Etanercept.
Glycopyrrolate	Glycopyrrolate Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Modafinil	Modafinil The metabolism of Haloperidol can be increased when combined with Armodafinil.
Perindopril	Perindopril Haloperidol may decrease the excretion rate of Perindopril which could result in a higher serum level.
Tenofovir	Tenofovir The serum concentration of Haloperidol can be increased when it is combined with Tenofovir.
Choline Magnesium Trisalicylate	Choline Magnesium Trisalicylate The therapeutic efficacy of Haloperidol can be increased when used in combination with Choline magnesium trisalicylate.
Sirolimus	Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Haloperidol.
Dutasteride	Dutasteride The metabolism of Dutasteride can be decreased when combined with Haloperidol.
Epinephrine Injection	Epinephrine Injection The serum concentration of Haloperidol can be increased when it is combined with Epinephrine.
Eplerenone	Eplerenone The metabolism of Eplerenone can be decreased when combined with Haloperidol.
Escitalopram	Escitalopram The serum concentration of Escitalopram can be increased when it is combined with Haloperidol.
Zonisamide	Zonisamide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Zonisamide.
Adalimumab Injection	Adalimumab Injection The metabolism of Haloperidol can be increased when combined with Adalimumab.
Aripiprazole	Aripiprazole The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Aripiprazole.
Atomoxetine	Atomoxetine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Atomoxetine.
Dexmethylphenidate	Dexmethylphenidate The risk or severity of CNS depression can be increased when Haloperidol is combined with Dexmethylphenidate.
Atazanavir	Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Haloperidol.
Almotriptan	Almotriptan The risk or severity of CNS depression can be increased when Almotriptan is combined with Haloperidol.
Eletriptan	Eletriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Eletriptan.
Mefloquine	Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Haloperidol.
Rosuvastatin	Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Haloperidol.
Vardenafil	Vardenafil The metabolism of Vardenafil can be decreased when combined with Haloperidol.
Alfuzosin	Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Haloperidol.
Aprepitant	Aprepitant The serum concentration of Haloperidol can be increased when it is combined with Aprepitant.
Emtricitabine	Emtricitabine Haloperidol may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Interferon Beta-1a Subcutaneous Injection	Interferon Beta-1a Subcutaneous Injection The metabolism of Haloperidol can be decreased when combined with Interferon beta-1a.
Memantine	Memantine The risk or severity of adverse effects can be increased when Haloperidol is combined with Memantine.
Tegaserod	Tegaserod The serum concentration of Haloperidol can be increased when it is combined with Tegaserod.
Tadalafil	Tadalafil The serum concentration of Tadalafil can be increased when it is combined with Haloperidol.
Fosamprenavir	Fosamprenavir The serum concentration of Haloperidol can be increased when it is combined with Fosamprenavir.
Frovatriptan	Frovatriptan The risk or severity of CNS depression can be increased when Haloperidol is combined with Frovatriptan.
Gemifloxacin	Gemifloxacin The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Gemifloxacin.
Progesterone	Progesterone The serum concentration of Haloperidol can be increased when it is combined with Progesterone.
Apomorphine Injection	Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Haloperidol.
Infliximab Injection	Infliximab Injection The metabolism of Haloperidol can be increased when combined with Infliximab.
Oxandrolone	Oxandrolone The metabolism of Haloperidol can be decreased when combined with Oxandrolone.
Protriptyline	Protriptyline The serum concentration of Haloperidol can be increased when it is combined with Protriptyline.
Rifaximin	Rifaximin The serum concentration of Haloperidol can be increased when it is combined with Rifaximin.
Duloxetine	Duloxetine The risk or severity of CNS depression can be increased when Duloxetine is combined with Haloperidol.
Norethindrone	Norethindrone The serum concentration of Norethisterone can be increased when it is combined with Haloperidol.
Tinidazole	Tinidazole The serum concentration of Tinidazole can be increased when it is combined with Haloperidol.
Trospium	Trospium The serum concentration of Trospium can be increased when it is combined with Haloperidol.
Bosentan	Bosentan The serum concentration of Haloperidol can be increased when it is combined with Bosentan.
Cefditoren	Cefditoren Haloperidol may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cinacalcet	Cinacalcet The serum concentration of Haloperidol can be increased when it is combined with Cinacalcet.
Cyanocobalamin Injection	Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Erlotinib	Erlotinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Erlotinib.
Eszopiclone	Eszopiclone The risk or severity of CNS depression can be increased when Haloperidol is combined with Eszopiclone.
Ganciclovir	Ganciclovir Haloperidol may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Insulin Aspart (rDNA Origin) Injection	Insulin Aspart (rDNA Origin) Injection The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Haloperidol.
Ribavirin	Ribavirin Haloperidol may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Solifenacin	Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Haloperidol.
Valganciclovir	Valganciclovir Haloperidol may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole	Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Haloperidol.
Adefovir	Adefovir Adefovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Dextroamphetamine	Dextroamphetamine The therapeutic efficacy of Amphetamine can be decreased when used in combination with Haloperidol.
Entecavir	Entecavir The metabolism of Haloperidol can be decreased when combined with Entecavir.
Peginterferon Alfa-2a Injection	Peginterferon Alfa-2a Injection The metabolism of Haloperidol can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron)	Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Haloperidol can be increased when it is combined with Peginterferon alfa-2b.
Pramlintide Injection	Pramlintide Injection The therapeutic efficacy of Pramlintide can be decreased when used in combination with Haloperidol.
Sodium Oxybate	Sodium Oxybate The risk or severity of CNS depression can be increased when Sodium oxybate is combined with Haloperidol.
Exenatide Injection	Exenatide Injection The therapeutic efficacy of Exenatide can be decreased when used in combination with Haloperidol.
Ibandronate	Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Haloperidol.
Isocarboxazid	Isocarboxazid The risk or severity of CNS depression can be increased when Haloperidol is combined with Isocarboxazid.
Ramelteon	Ramelteon The risk or severity of CNS depression can be increased when Haloperidol is combined with Ramelteon.
Darifenacin	Darifenacin The serum concentration of Darifenacin can be increased when it is combined with Haloperidol.
Fentanyl	Fentanyl The metabolism of Fentanyl can be decreased when combined with Haloperidol.
Pregabalin	Pregabalin The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin.
Deferasirox	Deferasirox The serum concentration of Haloperidol can be increased when it is combined with Deferasirox.
Phenylephrine	Phenylephrine The metabolism of Haloperidol can be increased when combined with Phenylephrine.
Tipranavir	Tipranavir The serum concentration of Tipranavir can be increased when it is combined with Haloperidol.
Felbamate	Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Haloperidol.
Insulin Detemir (rDNA Origin) Injection	Insulin Detemir (rDNA Origin) Injection The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Haloperidol.
Ranolazine	Ranolazine The metabolism of Ranolazine can be decreased when combined with Haloperidol.
Abatacept Injection	Abatacept Injection The metabolism of Haloperidol can be increased when combined with Abatacept.
Rasagiline	Rasagiline The risk or severity of CNS depression can be increased when Rasagiline is combined with Haloperidol.
Imatinib	Imatinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Imatinib.
Sitagliptin	Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Haloperidol.
Varenicline	Varenicline Haloperidol may decrease the excretion rate of Varenicline which could result in a higher serum level.
Gefitinib	Gefitinib The serum concentration of Haloperidol can be increased when it is combined with Gefitinib.
Albuterol	Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Haloperidol.
Paliperidone	Paliperidone The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Paliperidone.
Exemestane	Exemestane The serum concentration of Haloperidol can be increased when it is combined with Exemestane.
Bortezomib	Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Haloperidol.
Clofarabine Injection	Clofarabine Injection Haloperidol may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Insulin Glulisine (rDNA origin) Injection	Insulin Glulisine (rDNA origin) Injection The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Haloperidol.
Lubiprostone	Lubiprostone Haloperidol may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Oxaliplatin Injection	Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Oxaliplatin.
Posaconazole	Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Haloperidol.
Primaquine	Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Haloperidol.
Aliskiren	Aliskiren The serum concentration of Haloperidol can be increased when it is combined with Aliskiren.
Bismuth Subsalicylate	Bismuth Subsalicylate Haloperidol may increase the neurotoxic activities of Bismuth subsalicylate.
Darunavir	Darunavir The serum concentration of Darunavir can be increased when it is combined with Haloperidol.
Pemetrexed Injection	Pemetrexed Injection Haloperidol may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate	Dimenhydrinate The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dimenhydrinate.
Lisdexamfetamine	Lisdexamfetamine The therapeutic efficacy of Lisdexamfetamine can be decreased when used in combination with Haloperidol.
Nabilone	Nabilone The risk or severity of CNS depression can be increased when Nabilone is combined with Haloperidol.
Retapamulin	Retapamulin The metabolism of Retapamulin can be decreased when combined with Haloperidol.
Vorinostat	Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Haloperidol.
Sorafenib	Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Haloperidol.
Sunitinib	Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Haloperidol.
Dronabinol	Dronabinol The risk or severity of CNS depression can be increased when Dronabinol is combined with Haloperidol.
Lapatinib	Lapatinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Lapatinib.
Levocetirizine	Levocetirizine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Levocetirizine.
Pegaptanib Injection	Pegaptanib Injection Haloperidol may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib	Dasatinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dasatinib.
Mexiletine	Mexiletine The serum concentration of Haloperidol can be increased when it is combined with Mexiletine.
Armodafinil	Armodafinil The metabolism of Haloperidol can be increased when combined with Armodafinil.
Azacitidine Injection	Azacitidine Injection Haloperidol may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Ivermectin	Ivermectin The serum concentration of Haloperidol can be increased when it is combined with Ivermectin.
Temsirolimus	Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Haloperidol.
Maraviroc	Maraviroc The serum concentration of Maraviroc can be increased when it is combined with Haloperidol.
Lenalidomide	Lenalidomide Lenalidomide may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Nilotinib	Nilotinib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Nilotinib.
Toremifene	Toremifene The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Toremifene.
Bexarotene	Bexarotene The serum concentration of Haloperidol can be increased when it is combined with Bexarotene.
Budesonide	Budesonide The serum concentration of Haloperidol can be increased when it is combined with Budesonide.
Chloramphenicol Injection	Chloramphenicol Injection The serum concentration of Haloperidol can be increased when it is combined with Chloramphenicol.
Desmopressin	Desmopressin Desmopressin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
OnabotulinumtoxinA Injection	OnabotulinumtoxinA Injection The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol.
RimabotulinumtoxinB Injection	RimabotulinumtoxinB Injection The risk or severity of CNS depression can be increased when Botulinum Toxin Type B is combined with Haloperidol.
Doripenem Injection	Doripenem Injection Haloperidol may decrease the excretion rate of Doripenem which could result in a higher serum level.
Etravirine	Etravirine The serum concentration of Haloperidol can be increased when it is combined with Etravirine.
Arsenic Trioxide Injection	Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Arsenic trioxide.
Mitoxantrone Injection	Mitoxantrone Injection The serum concentration of Haloperidol can be increased when it is combined with Mitoxantrone.
Desvenlafaxine	Desvenlafaxine The risk or severity of CNS depression can be increased when Haloperidol is combined with Desvenlafaxine.
Cevimeline	Cevimeline The serum concentration of Cevimeline can be increased when it is combined with Haloperidol.
Nebivolol	Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Haloperidol.
Tretinoin	Tretinoin The serum concentration of Tretinoin can be increased when it is combined with Haloperidol.
Bendamustine Injection	Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Haloperidol.
Pilocarpine	Pilocarpine The serum concentration of Haloperidol can be increased when it is combined with Pilocarpine.
Flecainide	Flecainide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Flecainide.
Certolizumab Injection	Certolizumab Injection The metabolism of Haloperidol can be increased when combined with Certolizumab pegol.
Ixabepilone Injection	Ixabepilone Injection The serum concentration of Ixabepilone can be increased when it is combined with Haloperidol.
Irinotecan Injection	Irinotecan Injection The serum concentration of Irinotecan can be increased when it is combined with Haloperidol.
Daptomycin Injection	Daptomycin Injection Daptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Estramustine	Estramustine The serum concentration of Haloperidol can be increased when it is combined with Estramustine.
Praziquantel	Praziquantel The serum concentration of Praziquantel can be increased when it is combined with Haloperidol.
Methylnaltrexone Injection	Methylnaltrexone Injection Haloperidol may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide	Rufinamide The risk or severity of CNS depression can be increased when Rufinamide is combined with Haloperidol.
Silodosin	Silodosin The serum concentration of Haloperidol can be increased when it is combined with Silodosin.
Midazolam	Midazolam The serum concentration of Midazolam can be increased when it is combined with Haloperidol.
Dexrazoxane Injection	Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Eltrombopag	Eltrombopag The metabolism of Haloperidol can be decreased when combined with Eltrombopag.
Milnacipran	Milnacipran The risk or severity of CNS depression can be increased when Haloperidol is combined with Milnacipran.
Dexlansoprazole	Dexlansoprazole The serum concentration of Haloperidol can be increased when it is combined with Dexlansoprazole.
Plerixafor Injection	Plerixafor Injection Haloperidol may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Fesoterodine	Fesoterodine The serum concentration of Fesoterodine can be increased when it is combined with Haloperidol.
Degarelix Injection	Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Haloperidol.
Betaxolol	Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Haloperidol.
Iloperidone	Iloperidone The metabolism of Iloperidone can be decreased when combined with Haloperidol.
Prasugrel	Prasugrel The serum concentration of Prasugrel can be increased when it is combined with Haloperidol.
Lacosamide	Lacosamide The risk or severity of CNS depression can be increased when Haloperidol is combined with Lacosamide.
Everolimus	Everolimus The metabolism of Everolimus can be decreased when combined with Haloperidol.
Tolvaptan (low blood sodium)	Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Haloperidol.
Dronedarone	Dronedarone The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Dronedarone.
AbobotulinumtoxinA Injection	AbobotulinumtoxinA Injection The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol.
Pralatrexate Injection	Pralatrexate Injection Haloperidol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection	Palonosetron Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Palonosetron.
Saxagliptin	Saxagliptin The serum concentration of Saxagliptin can be increased when it is combined with Haloperidol.
Telavancin Injection	Telavancin Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Telavancin.
Romidepsin Injection	Romidepsin Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Romidepsin.
Tapentadol	Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Topotecan	Topotecan The serum concentration of Topotecan can be increased when it is combined with Haloperidol.
Golimumab Injection	Golimumab Injection The metabolism of Haloperidol can be increased when combined with Golimumab.
Pazopanib	Pazopanib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Pazopanib.
Asenapine	Asenapine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Asenapine.
Vigabatrin	Vigabatrin The risk or severity of CNS depression can be increased when Haloperidol is combined with Vigabatrin.
Pitavastatin	Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Haloperidol.
Albendazole	Albendazole The serum concentration of Albendazole can be increased when it is combined with Haloperidol.
Ulipristal	Ulipristal The serum concentration of Haloperidol can be increased when it is combined with Ulipristal.
Levonorgestrel	Levonorgestrel The serum concentration of Haloperidol can be increased when it is combined with Levonorgestrel.
Oxymorphone	Oxymorphone The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxymorphone.
Liraglutide Injection	Liraglutide Injection The therapeutic efficacy of Liraglutide can be decreased when used in combination with Haloperidol.
Tocilizumab Injection	Tocilizumab Injection The metabolism of Haloperidol can be increased when combined with Tocilizumab.
Dalfampridine	Dalfampridine The risk or severity of seizure can be increased when Haloperidol is combined with Dalfampridine.
Fingolimod	Fingolimod The risk or severity of QTc prolongation can be increased when Fingolimod is combined with Haloperidol.
Eribulin Injection	Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Haloperidol.
IncobotulinumtoxinA Injection	IncobotulinumtoxinA Injection The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Haloperidol.
Cabazitaxel Injection	Cabazitaxel Injection The serum concentration of Cabazitaxel can be increased when it is combined with Haloperidol.
Ceftaroline Injection	Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Lurasidone	Lurasidone The metabolism of Lurasidone can be decreased when combined with Haloperidol.
Acetaminophen Injection	Acetaminophen Injection The serum concentration of Haloperidol can be increased when it is combined with Acetaminophen.
Vilazodone	Vilazodone The risk or severity of CNS depression can be increased when Haloperidol is combined with Vilazodone.
Ipilimumab Injection	Ipilimumab Injection Haloperidol may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection	Denileukin Diftitox Injection The serum concentration of Haloperidol can be increased when it is combined with Aldesleukin.
Terbutaline Injection	Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Haloperidol.
Busulfan Injection	Busulfan Injection The serum concentration of Busulfan can be increased when it is combined with Haloperidol.
Roflumilast	Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Haloperidol.
Linagliptin	Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Haloperidol.
Rilpivirine	Rilpivirine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Rilpivirine.
Cyclophosphamide Injection	Cyclophosphamide Injection The serum concentration of Cyclophosphamide can be increased when it is combined with Haloperidol.
Abiraterone	Abiraterone The serum concentration of Haloperidol can be increased when it is combined with Abiraterone.
Triptorelin Injection	Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Haloperidol.
Rivaroxaban	Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Haloperidol.
Ticagrelor	Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Haloperidol.
Brentuximab Vedotin Injection	Brentuximab Vedotin Injection The serum concentration of Haloperidol can be increased when it is combined with Brentuximab vedotin.
Ruxolitinib	Ruxolitinib The serum concentration of Ruxolitinib can be increased when it is combined with Haloperidol.
Vandetanib	Vandetanib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Vandetanib.
Clobazam	Clobazam The risk or severity of CNS depression can be increased when Clobazam is combined with Haloperidol.
Vemurafenib	Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Haloperidol.
Vismodegib	Vismodegib The serum concentration of Haloperidol can be increased when it is combined with Vismodegib.
Ivacaftor	Ivacaftor The metabolism of Haloperidol can be decreased when combined with Ivacaftor.
Deferiprone	Deferiprone Haloperidol may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib	Axitinib The serum concentration of Axitinib can be increased when it is combined with Haloperidol.
Crizotinib	Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Haloperidol.
Cabergoline	Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Haloperidol.
Naloxone Injection	Naloxone Injection The serum concentration of Naloxone can be increased when it is combined with Haloperidol.
Ambrisentan	Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Haloperidol.
Fondaparinux Injection	Fondaparinux Injection Haloperidol may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Ezogabine	Ezogabine The risk or severity of CNS depression can be increased when Haloperidol is combined with Tiagabine.
Enzalutamide	Enzalutamide The serum concentration of Haloperidol can be increased when it is combined with Enzalutamide.
Mirabegron	Mirabegron The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Mirabegron.
Regorafenib	Regorafenib The serum concentration of Haloperidol can be increased when it is combined with Regorafenib.
Bosutinib	Bosutinib The serum concentration of Haloperidol can be increased when it is combined with Bosutinib.
Corticotropin, Repository Injection	Corticotropin, Repository Injection The serum concentration of Haloperidol can be increased when it is combined with Corticotropin.
Teriflunomide	Teriflunomide The serum concentration of Haloperidol can be decreased when it is combined with Teriflunomide.
Lorcaserin	Lorcaserin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Haloperidol.
Cabozantinib (thyroid cancer)	Cabozantinib (thyroid cancer) The serum concentration of Cabozantinib can be increased when it is combined with Haloperidol.
Teduglutide Injection	Teduglutide Injection Haloperidol may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline	Bedaquiline The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Bedaquiline.
Tofacitinib	Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Haloperidol.
Alogliptin	Alogliptin The serum concentration of Alogliptin can be increased when it is combined with Haloperidol.
Ponatinib	Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Haloperidol.
Pomalidomide	Pomalidomide The risk or severity of CNS depression can be increased when Haloperidol is combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection	Ado-trastuzumab Emtansine Injection The serum concentration of Trastuzumab emtansine can be increased when it is combined with Haloperidol.
Apixaban	Apixaban The serum concentration of Apixaban can be increased when it is combined with Haloperidol.
Canagliflozin	Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Haloperidol.
Methazolamide	Methazolamide Methazolamide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib	Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Haloperidol.
Ospemifene	Ospemifene The serum concentration of Ospemifene can be increased when it is combined with Haloperidol.
Trametinib	Trametinib Haloperidol may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran	Levomilnacipran The risk or severity of CNS depression can be increased when Haloperidol is combined with Levomilnacipran.
Ertapenem Injection	Ertapenem Injection Ertapenem may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Vortioxetine	Vortioxetine The risk or severity of CNS depression can be increased when Haloperidol is combined with Vortioxetine.
Perampanel	Perampanel The risk or severity of CNS depression can be increased when Perampanel is combined with Haloperidol.
Ibrutinib	Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Haloperidol.
Lomitapide	Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Haloperidol.
Avanafil	Avanafil The metabolism of Avanafil can be decreased when combined with Haloperidol.
Ketorolac Injection	Ketorolac Injection The therapeutic efficacy of Haloperidol can be increased when used in combination with Ketorolac.
Simeprevir	Simeprevir The serum concentration of Haloperidol can be increased when it is combined with Simeprevir.
Sofosbuvir	Sofosbuvir Haloperidol may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin	Dapagliflozin The serum concentration of Haloperidol can be increased when it is combined with Dapagliflozin.
Apremilast	Apremilast The serum concentration of Haloperidol can be increased when it is combined with Apremilast.
Droxidopa	Droxidopa Haloperidol may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Ceritinib	Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Haloperidol.
Siltuximab Injection	Siltuximab Injection The serum concentration of Haloperidol can be increased when it is combined with Siltuximab.
Albiglutide Injection	Albiglutide Injection The therapeutic efficacy of Albiglutide can be decreased when used in combination with Haloperidol.
Eslicarbazepine	Eslicarbazepine The risk or severity of CNS depression can be increased when Haloperidol is combined with Eslicarbazepine.
Belinostat Injection	Belinostat Injection The metabolism of Haloperidol can be increased when combined with Belinostat.
Idelalisib	Idelalisib The serum concentration of Haloperidol can be increased when it is combined with Idelalisib.
Testosterone Injection	Testosterone Injection The serum concentration of Testosterone can be increased when it is combined with Haloperidol.
Oritavancin Injection	Oritavancin Injection The serum concentration of Haloperidol can be increased when it is combined with Oritavancin.
Empagliflozin	Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Haloperidol.
Vorapaxar	Vorapaxar The serum concentration of Haloperidol can be increased when it is combined with Vorapaxar.
Hydrocodone	Hydrocodone Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant	Suvorexant Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection	Dulaglutide Injection The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Haloperidol.
Edoxaban	Edoxaban Haloperidol may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Peginterferon Beta-1a Injection	Peginterferon Beta-1a Injection The metabolism of Haloperidol can be decreased when combined with Peginterferon beta-1a.
Olaparib	Olaparib The metabolism of Olaparib can be decreased when combined with Haloperidol.
Methamphetamine	Methamphetamine The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Haloperidol.
Tasimelteon	Tasimelteon The risk or severity of CNS depression can be increased when Haloperidol is combined with Tasimelteon.
Riociguat	Riociguat The serum concentration of Haloperidol can be increased when it is combined with Riociguat.
Lanreotide Injection	Lanreotide Injection The serum concentration of Haloperidol can be increased when it is combined with Lanreotide.
Pirfenidone	Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Haloperidol.
Nintedanib	Nintedanib The serum concentration of Haloperidol can be increased when it is combined with Nintedanib.
Secukinumab Injection	Secukinumab Injection The metabolism of Haloperidol can be increased when combined with Secukinumab.
Risperidone Injection	Risperidone Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Risperidone.
Palbociclib	Palbociclib The serum concentration of Haloperidol can be increased when it is combined with Palbociclib.
Insulin Human Inhalation	Insulin Human Inhalation The therapeutic efficacy of Insulin human can be decreased when used in combination with Haloperidol.
Lenvatinib	Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Haloperidol.
Naloxegol	Naloxegol The metabolism of Naloxegol can be decreased when combined with Haloperidol.
Panobinostat	Panobinostat The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Panobinostat.
Ivabradine	Ivabradine The metabolism of Ivabradine can be decreased when combined with Haloperidol.
Amiloride	Amiloride Amiloride may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection	Isavuconazonium Injection The serum concentration of Haloperidol can be increased when it is combined with Isavuconazonium.
Macitentan	Macitentan The serum concentration of Macitentan can be increased when it is combined with Haloperidol.
Sonidegib	Sonidegib The metabolism of Sonidegib can be decreased when combined with Haloperidol.
Flibanserin	Flibanserin The metabolism of Haloperidol can be decreased when combined with Flibanserin.
Rolapitant	Rolapitant The serum concentration of Rolapitant can be increased when it is combined with Haloperidol.
Prednisolone	Prednisolone The serum concentration of Haloperidol can be increased when it is combined with Prednisolone.
Daclatasvir	Daclatasvir The serum concentration of Daclatasvir can be increased when it is combined with Haloperidol.
Brexpiprazole	Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Haloperidol.
Ziprasidone Injection	Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Haloperidol.
Cariprazine	Cariprazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Cariprazine.
Penicillin G Procaine Injection	Penicillin G Procaine Injection Haloperidol may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Insulin Degludec (rDNA Origin) Injection	Insulin Degludec (rDNA Origin) Injection The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Haloperidol.
Cobimetinib	Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Haloperidol.
Trabectedin Injection	Trabectedin Injection The serum concentration of Trabectedin can be increased when it is combined with Haloperidol.
Osimertinib	Osimertinib The serum concentration of Haloperidol can be increased when it is combined with Osimertinib.
Alectinib	Alectinib The metabolism of Alectinib can be decreased when combined with Haloperidol.
Ixazomib	Ixazomib The serum concentration of Ixazomib can be increased when it is combined with Haloperidol.
Rifapentine	Rifapentine The serum concentration of Haloperidol can be increased when it is combined with Rifapentine.
Lesinurad	Lesinurad Haloperidol may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection	Amphotericin B Liposomal Injection The serum concentration of Haloperidol can be increased when it is combined with Amphotericin B.
Dexamethasone Injection	Dexamethasone Injection The serum concentration of Haloperidol can be increased when it is combined with Dexamethasone.
Brivaracetam Injection	Brivaracetam Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Brivaracetam.
Venetoclax	Venetoclax The serum concentration of Haloperidol can be increased when it is combined with Venetoclax.
Cobicistat	Cobicistat The serum concentration of Haloperidol can be increased when it is combined with Cobicistat.
Selexipag	Selexipag The serum concentration of Haloperidol can be increased when it is combined with Selexipag.
Pimavanserin	Pimavanserin The risk or severity of CNS depression can be increased when Haloperidol is combined with Pimavanserin.
Obeticholic Acid	Obeticholic Acid The metabolism of Haloperidol can be decreased when combined with Obeticholic acid.
Diphenhydramine Injection	Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Diphenhydramine.
Furosemide Injection	Furosemide Injection Haloperidol may increase the excretion rate of Furosemide which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib	Rucaparib The serum concentration of Rucaparib can be increased when it is combined with Haloperidol.
Lixisenatide Injection	Lixisenatide Injection The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Haloperidol.
Ribociclib	Ribociclib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ribociclib.
Brigatinib	Brigatinib The serum concentration of Haloperidol can be increased when it is combined with Brigatinib.
Doxepin (Insomnia)	Doxepin (Insomnia) The serum concentration of Doxepin can be increased when it is combined with Haloperidol.
Deutetrabenazine	Deutetrabenazine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Deutetrabenazine.
Valbenazine	Valbenazine The serum concentration of Valbenazine can be increased when it is combined with Haloperidol.
Deflazacort	Deflazacort The serum concentration of Haloperidol can be increased when it is combined with Deflazacort.
Safinamide	Safinamide The risk or severity of CNS depression can be increased when Safinamide is combined with Haloperidol.
Naldemedine	Naldemedine Haloperidol may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Sarilumab Injection	Sarilumab Injection The serum concentration of Haloperidol can be increased when it is combined with Sarilumab.
Midostaurin	Midostaurin The serum concentration of Haloperidol can be increased when it is combined with Midostaurin.
Neratinib	Neratinib The serum concentration of Haloperidol can be increased when it is combined with Neratinib.
Enasidenib	Enasidenib The serum concentration of Haloperidol can be increased when it is combined with Enasidenib.
Aprepitant/Fosaprepitant Injection	Aprepitant/Fosaprepitant Injection The serum concentration of Fosaprepitant can be increased when it is combined with Haloperidol.
Benznidazole	Benznidazole Haloperidol may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Copanlisib Injection	Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Haloperidol.
Delafloxacin	Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Haloperidol.
Abemaciclib	Abemaciclib The serum concentration of Haloperidol can be increased when it is combined with Abemaciclib.
Acalabrutinib	Acalabrutinib The serum concentration of Haloperidol can be increased when it is combined with Acalabrutinib.
Letermovir	Letermovir The serum concentration of Letermovir can be increased when it is combined with Haloperidol.
Semaglutide Injection	Semaglutide Injection The therapeutic efficacy of Semaglutide can be decreased when used in combination with Haloperidol.
Tetrabenazine	Tetrabenazine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Tetrabenazine.
Ertugliflozin	Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Haloperidol.
Buprenorphine Injection	Buprenorphine Injection Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide	Apalutamide The serum concentration of Haloperidol can be increased when it is combined with Apalutamide.
Fostamatinib	Fostamatinib The serum concentration of Haloperidol can be increased when it is combined with Fostamatinib.
Avatrombopag	Avatrombopag The metabolism of Haloperidol can be increased when combined with Avatrombopag.
Baricitinib	Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Haloperidol.
Lofexidine	Lofexidine The therapeutic efficacy of Haloperidol can be increased when used in combination with Lofexidine.
Plazomicin Injection	Plazomicin Injection Haloperidol may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat	Eliglustat The metabolism of Eliglustat can be decreased when combined with Haloperidol.
Encorafenib	Encorafenib The serum concentration of Encorafenib can be increased when it is combined with Haloperidol.
Binimetinib	Binimetinib The metabolism of Binimetinib can be decreased when combined with Haloperidol.
Ivosidenib	Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Haloperidol.
Elagolix	Elagolix The serum concentration of Elagolix can be increased when it is combined with Haloperidol.
Eravacycline Injection	Eravacycline Injection The serum concentration of Haloperidol can be increased when it is combined with Eravacycline.
Doravirine	Doravirine The serum concentration of Doravirine can be increased when it is combined with Haloperidol.
Tafenoquine	Tafenoquine The serum concentration of Tafenoquine can be increased when it is combined with Haloperidol.
Cannabidiol	Cannabidiol The risk or severity of CNS depression can be increased when Cannabidiol is combined with Haloperidol.
Dacomitinib	Dacomitinib The serum concentration of Haloperidol can be increased when it is combined with Dacomitinib.
Duvelisib	Duvelisib The serum concentration of Haloperidol can be increased when it is combined with Duvelisib.
Stiripentol	Stiripentol The risk or severity of CNS depression can be increased when Stiripentol is combined with Haloperidol.
Gilteritinib	Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Haloperidol.
Glasdegib	Glasdegib The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Glasdegib.
Lorlatinib	Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Haloperidol.
Larotrectinib	Larotrectinib The serum concentration of Haloperidol can be increased when it is combined with Larotrectinib.
Paclitaxel (with albumin) Injection	Paclitaxel (with albumin) Injection The serum concentration of Paclitaxel can be increased when it is combined with Haloperidol.
Rifamycin	Rifamycin The serum concentration of Haloperidol can be increased when it is combined with Rifamycin.
Prucalopride	Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Haloperidol.
Emapalumab-lzsg Injection	Emapalumab-lzsg Injection The metabolism of Haloperidol can be increased when combined with Emapalumab.
Siponimod	Siponimod The risk or severity of adverse effects can be increased when Haloperidol is combined with Siponimod.
Acyclovir Ophthalmic	Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Erdafitinib	Erdafitinib The serum concentration of Erdafitinib can be increased when it is combined with Haloperidol.
Esomeprazole Injection	Esomeprazole Injection The serum concentration of Haloperidol can be increased when it is combined with Esomeprazole.
Alpelisib	Alpelisib The serum concentration of Haloperidol can be increased when it is combined with Alpelisib.
Brexanolone Injection	Brexanolone Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Brexanolone.
Polatuzumab vedotin-piiq Injection	Polatuzumab vedotin-piiq Injection The serum concentration of Haloperidol can be increased when it is combined with Polatuzumab vedotin.
Solriamfetol	Solriamfetol The risk or severity of CNS depression can be increased when Haloperidol is combined with Solriamfetol.
Selinexor	Selinexor The serum concentration of Haloperidol can be increased when it is combined with Selinexor.
Darolutamide	Darolutamide The serum concentration of Haloperidol can be increased when it is combined with Darolutamide.
Triclabendazole	Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Haloperidol.
Entrectinib	Entrectinib The metabolism of Entrectinib can be decreased when combined with Haloperidol.
Pexidartinib	Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Haloperidol.
Upadacitinib	Upadacitinib The serum concentration of Haloperidol can be increased when it is combined with Upadacitinib.
Istradefylline	Istradefylline The serum concentration of Istradefylline can be increased when it is combined with Haloperidol.
Pitolisant	Pitolisant The serum concentration of Haloperidol can be decreased when it is combined with Pitolisant.
Pretomanid	Pretomanid The serum concentration of Pretomanid can be increased when it is combined with Haloperidol.
Fedratinib	Fedratinib The serum concentration of Haloperidol can be increased when it is combined with Fedratinib.
Lefamulin	Lefamulin Haloperidol may increase the QTc-prolonging activities of Lefamulin.
Phenytoin Injection	Phenytoin Injection The risk or severity of CNS depression can be increased when Phenytoin is combined with Haloperidol.
Fosphenytoin Injection	Fosphenytoin Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Fosphenytoin.
Enfortumab vedotin-ejfv Injection	Enfortumab vedotin-ejfv Injection The serum concentration of Haloperidol can be increased when it is combined with Enfortumab vedotin.
Zanubrutinib	Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Haloperidol.
Voxelotor	Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Haloperidol.
Avapritinib	Avapritinib The serum concentration of Avapritinib can be increased when it is combined with Haloperidol.
Lumateperone	Lumateperone The serum concentration of Lumateperone can be increased when it is combined with Haloperidol.
Lasmiditan	Lasmiditan The risk or severity of CNS depression can be increased when Haloperidol is combined with Lasmiditan.
Ubrogepant	Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Haloperidol.
Tazemetostat	Tazemetostat The serum concentration of Haloperidol can be increased when it is combined with Tazemetostat.
Cenobamate	Cenobamate The serum concentration of Haloperidol can be decreased when it is combined with Cenobamate.
Pemigatinib	Pemigatinib The metabolism of Pemigatinib can be decreased when combined with Haloperidol.
Selumetinib	Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Haloperidol.
Rimegepant	Rimegepant The metabolism of Rimegepant can be decreased when combined with Haloperidol.
Tucatinib	Tucatinib The metabolism of Tucatinib can be decreased when combined with Haloperidol.
Remdesivir Injection	Remdesivir Injection The serum concentration of Haloperidol can be increased when it is combined with Remdesivir.
Ripretinib	Ripretinib The serum concentration of Haloperidol can be increased when it is combined with Ripretinib.
Selpercatinib	Selpercatinib The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Haloperidol.
Capmatinib	Capmatinib The serum concentration of Haloperidol can be increased when it is combined with Capmatinib.
Lemborexant	Lemborexant The risk or severity of CNS depression can be increased when Haloperidol is combined with Lemborexant.
Fenfluramine	Fenfluramine The risk or severity of CNS depression can be increased when Fenfluramine is combined with Haloperidol.
Fostemsavir	Fostemsavir The serum concentration of Haloperidol can be increased when it is combined with Fostemsavir.
Lurbinectedin Injection	Lurbinectedin Injection The serum concentration of Lurbinectedin can be increased when it is combined with Haloperidol.
Octreotide	Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Haloperidol.
Pralsetinib	Pralsetinib The serum concentration of Haloperidol can be increased when it is combined with Pralsetinib.
Opicapone	Opicapone The therapeutic efficacy of Opicapone can be decreased when used in combination with Haloperidol.
Satralizumab-mwge Injection	Satralizumab-mwge Injection The serum concentration of Haloperidol can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection	Naxitamab-gqgk Injection Haloperidol may increase the neurotoxic activities of Naxitamab.
Relugolix	Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Haloperidol.
Progestin-Only (drospirenone) Oral Contraceptives	Progestin-Only (drospirenone) Oral Contraceptives The serum concentration of Haloperidol can be increased when it is combined with Drospirenone.
Viloxazine	Viloxazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Viloxazine.
Vitamin E (Alpha-Tocopherol)	Vitamin E (Alpha-Tocopherol) The serum concentration of Haloperidol can be increased when it is combined with Vitamin E.
Tobramycin Injection	Tobramycin Injection Tobramycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Theophylline	Theophylline The serum concentration of Theophylline can be increased when it is combined with Haloperidol.
Fenoprofen	Fenoprofen The therapeutic efficacy of Haloperidol can be increased when used in combination with Fenoprofen.
Indomethacin	Indomethacin The therapeutic efficacy of Haloperidol can be increased when used in combination with Indomethacin.
Mefenamic Acid	Mefenamic Acid The therapeutic efficacy of Haloperidol can be increased when used in combination with Mefenamic acid.
Naproxen	Naproxen The therapeutic efficacy of Haloperidol can be increased when used in combination with Naproxen.
Tolmetin	Tolmetin The therapeutic efficacy of Haloperidol can be increased when used in combination with Tolmetin.
Sulindac	Sulindac The therapeutic efficacy of Haloperidol can be increased when used in combination with Sulindac.
Trazodone	Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Haloperidol.
Isotretinoin	Isotretinoin The serum concentration of Isotretinoin can be increased when it is combined with Haloperidol.
Sucralfate	Sucralfate Sucralfate may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Hydroxyurea	Hydroxyurea The serum concentration of Haloperidol can be increased when it is combined with Hydroxyurea.
Floxuridine	Floxuridine The metabolism of Haloperidol can be decreased when combined with Floxuridine.
Phenobarbital	Phenobarbital The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenobarbital.
Metaxalone	Metaxalone The risk or severity of CNS depression can be increased when Haloperidol is combined with Metaxalone.
Methotrexate Injection	Methotrexate Injection The serum concentration of Haloperidol can be increased when it is combined with Methotrexate.
Levorphanol	Levorphanol The risk or severity of CNS depression can be increased when Haloperidol is combined with Levorphanol.
Primidone	Primidone The risk or severity of CNS depression can be increased when Haloperidol is combined with Primidone.
Methsuximide	Methsuximide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Methsuximide.
Diethylpropion	Diethylpropion The therapeutic efficacy of Diethylpropion can be decreased when used in combination with Haloperidol.
Chlorpromazine	Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Haloperidol.
Diazepam	Diazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Diazepam.
Oxazepam	Oxazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxazepam.
Flurazepam	Flurazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Flurazepam.
Clorazepate	Clorazepate The risk or severity of CNS depression can be increased when Haloperidol is combined with Clorazepic acid.
Lorazepam	Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Haloperidol.
Carmustine	Carmustine The metabolism of Haloperidol can be decreased when combined with Carmustine.
Amantadine	Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Haloperidol.
Codeine	Codeine The risk or severity of CNS depression can be increased when Haloperidol is combined with Codeine.
Meprobamate	Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Haloperidol.
Chlordiazepoxide	Chlordiazepoxide The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Haloperidol.
Bromocriptine	Bromocriptine The risk or severity of CNS depression can be increased when Haloperidol is combined with Bromocriptine.
Tranylcypromine	Tranylcypromine The risk or severity of CNS depression can be increased when Haloperidol is combined with Tranylcypromine.
Phenelzine	Phenelzine The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenelzine.
Procarbazine	Procarbazine The risk or severity of CNS depression can be increased when Procarbazine is combined with Haloperidol.
Ergoloid Mesylates	Ergoloid Mesylates The risk or severity of CNS depression can be increased when Ergoloid mesylate is combined with Haloperidol.
Tetracycline	Tetracycline The serum concentration of Tetracycline can be increased when it is combined with Haloperidol.
Minocycline	Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Prochlorperazine	Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Haloperidol.
Thioridazine	Thioridazine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Thioridazine.
Trifluoperazine	Trifluoperazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Trifluoperazine.
Bleomycin	Bleomycin Bleomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Dapsone	Dapsone The serum concentration of Haloperidol can be increased when it is combined with Dapsone.
Sulfadiazine	Sulfadiazine The serum concentration of Sulfadiazine can be increased when it is combined with Haloperidol.
Oxycodone	Oxycodone The risk or severity of CNS depression can be increased when Oxycodone is combined with Haloperidol.
Methadone	Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol.
Oxybutynin	Oxybutynin The serum concentration of Oxybutynin can be increased when it is combined with Haloperidol.
Benztropine	Benztropine The risk or severity of adverse effects can be increased when Haloperidol is combined with Benzatropine.
Maprotiline	Maprotiline The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Maprotiline.
Ibuprofen	Ibuprofen The serum concentration of Haloperidol can be increased when it is combined with Ibuprofen.
Trihexyphenidyl	Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Haloperidol.
Orphenadrine	Orphenadrine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Orphenadrine.
Perphenazine	Perphenazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Perphenazine.
Azathioprine	Azathioprine The metabolism of Azathioprine can be decreased when combined with Haloperidol.
Fluphenazine	Fluphenazine The risk or severity of CNS depression can be increased when Haloperidol is combined with Fluphenazine.
Phentermine	Phentermine The therapeutic efficacy of Phentermine can be decreased when used in combination with Haloperidol.
Methylphenidate	Methylphenidate The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
Amoxapine	Amoxapine The serum concentration of Amoxapine can be increased when it is combined with Haloperidol.
Sulfasalazine	Sulfasalazine The therapeutic efficacy of Haloperidol can be increased when used in combination with Sulfasalazine.
Hydrocortisone	Hydrocortisone The serum concentration of Hydrocortisone can be increased when it is combined with Haloperidol.
Doxorubicin	Doxorubicin The serum concentration of Haloperidol can be increased when it is combined with Doxorubicin.
Phenazopyridine	Phenazopyridine Phenazopyridine may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Carbamazepine	Carbamazepine The metabolism of Carbamazepine can be increased when combined with Haloperidol.
Molindone	Molindone The risk or severity of CNS depression can be increased when Haloperidol is combined with Molindone.
Methyldopa	Methyldopa Haloperidol may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Clonidine	Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Haloperidol.
Hydralazine	Hydralazine The serum concentration of Hydralazine can be increased when it is combined with Haloperidol.
Cimetidine	Cimetidine The serum concentration of Haloperidol can be increased when it is combined with Cimetidine.
Gentamicin Injection	Gentamicin Injection Gentamicin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Warfarin	Warfarin The serum concentration of Warfarin can be increased when it is combined with Haloperidol.
Clonazepam	Clonazepam The risk or severity of CNS depression can be increased when Haloperidol is combined with Clonazepam.
Loperamide	Loperamide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Loperamide.
Promethazine	Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Haloperidol.
Meclofenamate	Meclofenamate The therapeutic efficacy of Haloperidol can be increased when used in combination with Meclofenamic acid.
Daunorubicin	Daunorubicin The serum concentration of Haloperidol can be increased when it is combined with Daunorubicin.
Nitrofurantoin	Nitrofurantoin Haloperidol may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Griseofulvin	Griseofulvin The metabolism of Haloperidol can be increased when combined with Griseofulvin.
Digoxin	Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Haloperidol.
Loxapine	Loxapine The risk or severity of CNS depression can be increased when Loxapine is combined with Haloperidol.
Chloroquine	Chloroquine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Chloroquine.
Quinine	Quinine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Quinine.
Ethosuximide	Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Haloperidol.
Calcitriol	Calcitriol The serum concentration of Haloperidol can be increased when it is combined with Calcitriol.
Triamterene	Triamterene The metabolism of Haloperidol can be decreased when combined with Triamterene.
Sulfinpyrazone	Sulfinpyrazone The serum concentration of Haloperidol can be increased when it is combined with Sulfinpyrazone.
Chlorothiazide	Chlorothiazide Chlorothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone	Chlorthalidone Chlorthalidone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone	Metolazone Haloperidol may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide	Isosorbide Isosorbide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Clindamycin Injection	Clindamycin Injection The serum concentration of Clindamycin can be increased when it is combined with Haloperidol.
Secobarbital	Secobarbital The risk or severity of CNS depression can be increased when Secobarbital is combined with Haloperidol.
Desipramine	Desipramine The serum concentration of Desipramine can be increased when it is combined with Haloperidol.
Amitriptyline	Amitriptyline The serum concentration of Haloperidol can be increased when it is combined with Amitriptyline.
Imipramine	Imipramine The serum concentration of Haloperidol can be increased when it is combined with Imipramine.
Probenecid	Probenecid The metabolism of Probenecid can be decreased when combined with Haloperidol.
Quinidine	Quinidine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Quinidine.
Procainamide	Procainamide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Procainamide.
Isoniazid	Isoniazid The serum concentration of Isoniazid can be increased when it is combined with Haloperidol.
Pyrazinamide	Pyrazinamide Pyrazinamide may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Rifampin	Rifampin The metabolism of Haloperidol can be increased when combined with Rifampicin.
Disopyramide	Disopyramide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Disopyramide.
Valproic Acid	Valproic Acid The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Haloperidol.
Tamoxifen	Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Haloperidol.
Butabarbital	Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Haloperidol.
Liothyronine	Liothyronine Liothyronine may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Methimazole	Methimazole The serum concentration of Haloperidol can be increased when it is combined with Methimazole.
Chlorpropamide	Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Haloperidol.
Tolbutamide	Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Haloperidol.
Tolazamide	Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Haloperidol.
Dextromethorphan	Dextromethorphan The risk or severity of CNS depression can be increased when Dextromethorphan is combined with Haloperidol.
Cyclobenzaprine	Cyclobenzaprine The risk or severity of CNS depression can be increased when Haloperidol is combined with Cyclobenzaprine.
Niacin	Niacin The serum concentration of Haloperidol can be increased when it is combined with Niacin.
Baclofen	Baclofen The risk or severity of CNS depression can be increased when Baclofen is combined with Haloperidol.
Doxylamine	Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Cyproheptadine	Cyproheptadine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Cyproheptadine.
Clemastine	Clemastine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Clemastine.
Chlorpheniramine	Chlorpheniramine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Chlorpheniramine.
Brompheniramine	Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Haloperidol.
Meclizine	Meclizine The risk or severity of CNS depression can be increased when Haloperidol is combined with Meclizine.
Ethambutol	Ethambutol Ethambutol may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Methyclothiazide	Methyclothiazide Methyclothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide	Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Haloperidol.
Dantrolene	Dantrolene The risk or severity of CNS depression can be increased when Haloperidol is combined with Dantrolene.
Chlorzoxazone	Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Haloperidol.
Carisoprodol	Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Haloperidol.
Methocarbamol	Methocarbamol The risk or severity of CNS depression can be increased when Methocarbamol is combined with Haloperidol.
Pyridoxine	Pyridoxine Pyridoxine may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Folic Acid	Folic Acid Folic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Danazol	Danazol The serum concentration of Haloperidol can be increased when it is combined with Danazol.
Disulfiram	Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Haloperidol.
Propranolol (Cardiovascular)	Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Propranolol.
Pseudoephedrine	Pseudoephedrine The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Haloperidol.
Nortriptyline	Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Haloperidol.
Spironolactone	Spironolactone Spironolactone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection	Amphotericin B Injection The serum concentration of Haloperidol can be increased when it is combined with Amphotericin B.
Phytonadione	Phytonadione Haloperidol may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection	Amikacin Injection Amikacin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Nadolol	Nadolol The serum concentration of Nadolol can be increased when it is combined with Haloperidol.
Butorphanol Injection	Butorphanol Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Butorphanol.
Nalbuphine Injection	Nalbuphine Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Nalbuphine.
Allopurinol	Allopurinol Allopurinol may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Oxytocin Injection	Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Haloperidol.
Trimethobenzamide	Trimethobenzamide The risk or severity of CNS depression can be increased when Haloperidol is combined with Trimethobenzamide.
Flavoxate	Flavoxate Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine	Papaverine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Papaverine.
Fluorouracil Injection	Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Fluorouracil.
Colchicine	Colchicine The metabolism of Colchicine can be decreased when combined with Haloperidol.
Cefaclor	Cefaclor Cefaclor may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefadroxil	Cefadroxil Cefadroxil may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefazolin Injection	Cefazolin Injection Cefazolin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cephalexin	Cephalexin The serum concentration of Haloperidol can be increased when it is combined with Cephalexin.
Cefoxitin Injection	Cefoxitin Injection Cefoxitin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Dacarbazine	Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Haloperidol.
Acetazolamide	Acetazolamide The risk or severity of CNS depression can be increased when Haloperidol is combined with Acetazolamide.
Cefotaxime Injection	Cefotaxime Injection Cefotaxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Calcitonin Salmon Injection	Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Ketoconazole	Ketoconazole The metabolism of Haloperidol can be decreased when combined with Ketoconazole.
Pyrantel	Pyrantel The risk or severity of CNS depression can be increased when Haloperidol is combined with Pyrantel.
Thiotepa Injection	Thiotepa Injection The serum concentration of Haloperidol can be increased when it is combined with Thiotepa.
Vincristine Injection	Vincristine Injection The serum concentration of Vincristine can be increased when it is combined with Haloperidol.
Vinblastine	Vinblastine The serum concentration of Haloperidol can be increased when it is combined with Vinblastine.
Ethacrynic Acid	Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Colistimethate Injection	Colistimethate Injection Colistimethate may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Metoprolol	Metoprolol The serum concentration of Haloperidol can be increased when it is combined with Metoprolol.
Hydroxyzine	Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Haloperidol.
Thiothixene	Thiothixene The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Thiothixene.
Aspirin	Aspirin The therapeutic efficacy of Haloperidol can be increased when used in combination with Acetylsalicylic acid.
Salsalate	Salsalate The therapeutic efficacy of Haloperidol can be increased when used in combination with Salsalate.
Alprazolam	Alprazolam The metabolism of Alprazolam can be decreased when combined with Haloperidol.
Temazepam	Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Haloperidol.
Triazolam	Triazolam The risk or severity of CNS depression can be increased when Haloperidol is combined with Triazolam.
Dicyclomine	Dicyclomine Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine	Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Haloperidol.
Propantheline	Propantheline Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim	Trimethoprim The serum concentration of Haloperidol can be increased when it is combined with Trimethoprim.
Diltiazem	Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Haloperidol.
Nifedipine	Nifedipine The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Haloperidol.
Timolol	Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Haloperidol.
Verapamil	Verapamil The serum concentration of Haloperidol can be increased when it is combined with Verapamil.
Atenolol	Atenolol The serum concentration of Atenolol can be increased when it is combined with Haloperidol.
Pindolol	Pindolol The risk or severity of CNS depression can be increased when Haloperidol is combined with Pindolol.
Cisplatin Injection	Cisplatin Injection Haloperidol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal	Diflunisal The therapeutic efficacy of Haloperidol can be increased when used in combination with Diflunisal.
Piroxicam	Piroxicam The therapeutic efficacy of Haloperidol can be increased when used in combination with Piroxicam.
Bumetanide	Bumetanide Haloperidol may increase the excretion rate of Bumetanide which could result in a lower serum level and potentially a reduction in efficacy.
Streptozocin	Streptozocin The metabolism of Haloperidol can be increased when combined with Streptozocin.
Etoposide	Etoposide The serum concentration of Etoposide can be increased when it is combined with Haloperidol.
Glyburide	Glyburide The serum concentration of Haloperidol can be increased when it is combined with Glyburide.
Glipizide	Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Haloperidol.
Indapamide	Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Haloperidol.
Amoxicillin	Amoxicillin Haloperidol may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Nafcillin Injection	Nafcillin Injection The metabolism of Haloperidol can be increased when combined with Nafcillin.
Oxacillin Injection	Oxacillin Injection Haloperidol may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Pentoxifylline	Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Haloperidol.
Pentamidine Injection	Pentamidine Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Pentamidine.
Ceftriaxone Injection	Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Labetalol	Labetalol The serum concentration of Haloperidol can be increased when it is combined with Labetalol.
Auranofin	Auranofin Haloperidol may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection	Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Haloperidol.
Gemfibrozil	Gemfibrozil The serum concentration of Haloperidol can be increased when it is combined with Gemfibrozil.
Guanabenz	Guanabenz The metabolism of Guanabenz can be decreased when combined with Haloperidol.
Dipivefrin Ophthalmic	Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Ceftazidime Injection	Ceftazidime Injection Ceftazidime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Ketoprofen	Ketoprofen The therapeutic efficacy of Haloperidol can be increased when used in combination with Ketoprofen.
Cefotetan Injection	Cefotetan Injection Cefotetan may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Pimozide	Pimozide The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Pimozide.
Flurbiprofen	Flurbiprofen The therapeutic efficacy of Haloperidol can be increased when used in combination with Flurbiprofen.
Amiodarone	Amiodarone The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Amiodarone.
Aztreonam Injection	Aztreonam Injection Aztreonam may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Buspirone	Buspirone The serum concentration of Buspirone can be increased when it is combined with Haloperidol.
Lovastatin	Lovastatin The metabolism of Lovastatin can be decreased when combined with Haloperidol.
Ciprofloxacin	Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Haloperidol.
Mesalamine	Mesalamine The therapeutic efficacy of Haloperidol can be increased when used in combination with Mesalazine.
Diclofenac	Diclofenac The serum concentration of Haloperidol can be increased when it is combined with Diclofenac.
Fluoxetine	Fluoxetine The metabolism of Haloperidol can be decreased when combined with Fluoxetine.
Nimodipine	Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Haloperidol.
Interferon Alfa-2b Injection	Interferon Alfa-2b Injection The metabolism of Haloperidol can be decreased when combined with Interferon alfa-2b.
Clozapine	Clozapine The risk or severity of QTc prolongation can be increased when Clozapine is combined with Haloperidol.
Estazolam	Estazolam The risk or severity of CNS depression can be increased when Haloperidol is combined with Estazolam.
Idarubicin	Idarubicin The serum concentration of Idarubicin can be increased when it is combined with Haloperidol.
Ofloxacin	Ofloxacin The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ofloxacin.
Didanosine	Didanosine Haloperidol may decrease the excretion rate of Didanosine which could result in a higher serum level.
Pentostatin Injection	Pentostatin Injection Haloperidol may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Clarithromycin	Clarithromycin The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Haloperidol.
Etodolac	Etodolac The therapeutic efficacy of Haloperidol can be increased when used in combination with Etodolac.
Felodipine	Felodipine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Felodipine.
Fosinopril	Fosinopril Fosinopril may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Nabumetone	Nabumetone The therapeutic efficacy of Haloperidol can be increased when used in combination with Nabumetone.
Simvastatin	Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Haloperidol.
Amlodipine	Amlodipine The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Haloperidol.
Teniposide Injection	Teniposide Injection The serum concentration of Haloperidol can be increased when it is combined with Teniposide.
Itraconazole	Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Haloperidol.
Lisinopril	Lisinopril Haloperidol may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Oxaprozin	Oxaprozin The therapeutic efficacy of Haloperidol can be increased when used in combination with Oxaprozin.
Atovaquone	Atovaquone The serum concentration of Haloperidol can be increased when it is combined with Atovaquone.
Rifabutin	Rifabutin The serum concentration of Haloperidol can be increased when it is combined with Rifabutin.
Sotalol	Sotalol The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Sotalol.
Bisoprolol	Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Haloperidol.
Zolpidem	Zolpidem Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin	Doxazosin The serum concentration of Doxazosin can be increased when it is combined with Haloperidol.
Isradipine	Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Haloperidol.
Omeprazole	Omeprazole The serum concentration of Haloperidol can be increased when it is combined with Omeprazole.
Cisapride	Cisapride The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Cisapride.
Gabapentin	Gabapentin The risk or severity of CNS depression can be increased when Haloperidol is combined with Gabapentin.
Fluvastatin	Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Haloperidol.
Venlafaxine	Venlafaxine The serum concentration of Haloperidol can be increased when it is combined with Venlafaxine.
Stavudine	Stavudine Haloperidol may increase the neurotoxic activities of Stavudine.
Famciclovir	Famciclovir The serum concentration of Famciclovir can be increased when it is combined with Haloperidol.
Fluvoxamine	Fluvoxamine The risk or severity of CNS depression can be increased when Fluvoxamine is combined with Haloperidol.
Nefazodone	Nefazodone The risk or severity of CNS depression can be increased when Haloperidol is combined with Nefazodone.
Lamotrigine	Lamotrigine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Lamotrigine.
Losartan	Losartan The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Losartan.
Valacyclovir	Valacyclovir Valaciclovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Tramadol	Tramadol The metabolism of Haloperidol can be decreased when combined with Tramadol.
Vinorelbine Injection	Vinorelbine Injection The serum concentration of Haloperidol can be increased when it is combined with Vinorelbine.
Carboplatin Injection	Carboplatin Injection Carboplatin may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Moexipril	Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Haloperidol.
Lansoprazole	Lansoprazole The serum concentration of Haloperidol can be increased when it is combined with Lansoprazole.
Ifosfamide Injection	Ifosfamide Injection The serum concentration of Ifosfamide can be increased when it is combined with Haloperidol.
Nicardipine	Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Haloperidol.
Bupropion	Bupropion The risk or severity of seizure can be increased when Haloperidol is combined with Bupropion.
Ticlopidine	Ticlopidine The serum concentration of Haloperidol can be increased when it is combined with Ticlopidine.
Saquinavir	Saquinavir The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Saquinavir.
Metformin	Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Haloperidol.
Nisoldipine	Nisoldipine The serum concentration of Nisoldipine can be increased when it is combined with Haloperidol.
Lamivudine	Lamivudine Haloperidol may decrease the excretion rate of Lamivudine which could result in a higher serum level.
Riluzole	Riluzole The risk or severity of CNS depression can be increased when Haloperidol is combined with Riluzole.
Acarbose	Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Haloperidol.
Glimepiride	Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Haloperidol.
Gemcitabine Injection	Gemcitabine Injection Gemcitabine may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Indinavir	Indinavir The serum concentration of Indinavir can be increased when it is combined with Haloperidol.
Ritonavir	Ritonavir The serum concentration of Haloperidol can be increased when it is combined with Ritonavir.
Docetaxel Injection	Docetaxel Injection The serum concentration of Docetaxel can be increased when it is combined with Haloperidol.
Cidofovir Injection	Cidofovir Injection Cidofovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Meropenem Injection	Meropenem Injection Haloperidol may decrease the excretion rate of Meropenem which could result in a higher serum level.
Clomipramine	Clomipramine The serum concentration of Clomipramine can be increased when it is combined with Haloperidol.
Zafirlukast	Zafirlukast The serum concentration of Haloperidol can be increased when it is combined with Zafirlukast.
Fosfomycin	Fosfomycin Haloperidol may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Mirtazapine	Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Haloperidol.
Topiramate	Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Haloperidol.
Zileuton	Zileuton The serum concentration of Zileuton can be increased when it is combined with Haloperidol.
Valsartan	Valsartan The metabolism of Haloperidol can be decreased when combined with Valsartan.
Insulin Lispro Injection	Insulin Lispro Injection The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Haloperidol.
Pramipexole	Pramipexole The therapeutic efficacy of Pramipexole can be decreased when used in combination with Haloperidol.
Donepezil	Donepezil The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Donepezil.
Nelfinavir	Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Haloperidol.
Azithromycin	Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Haloperidol.
Loratadine	Loratadine The risk or severity of QTc prolongation can be increased when Loratadine is combined with Haloperidol.
Carvedilol	Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Haloperidol.
Nilutamide	Nilutamide The metabolism of Haloperidol can be decreased when combined with Nilutamide.
Flutamide	Flutamide The serum concentration of Haloperidol can be increased when it is combined with Flutamide.
Selegiline	Selegiline The risk or severity of CNS depression can be increased when Haloperidol is combined with Selegiline.
Bicalutamide	Bicalutamide The serum concentration of Haloperidol can be increased when it is combined with Bicalutamide.
Sertraline	Sertraline The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Sertraline.
Propafenone	Propafenone The risk or severity of QTc prolongation can be increased when Propafenone is combined with Haloperidol.
Letrozole	Letrozole The serum concentration of Haloperidol can be increased when it is combined with Letrozole.
Raloxifene	Raloxifene The serum concentration of Haloperidol can be increased when it is combined with Raloxifene.
Irbesartan	Irbesartan The serum concentration of Irbesartan can be increased when it is combined with Haloperidol.
Tamsulosin	Tamsulosin The serum concentration of Tamsulosin can be increased when it is combined with Haloperidol.
Ropinirole	Ropinirole The therapeutic efficacy of Ropinirole can be decreased when used in combination with Haloperidol.
Finasteride	Finasteride The serum concentration of Finasteride can be increased when it is combined with Haloperidol.
Quetiapine	Quetiapine The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Quetiapine.
Cefepime Injection	Cefepime Injection Cefepime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefprozil	Cefprozil Cefprozil may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cefpodoxime	Cefpodoxime Cefpodoxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Cetirizine	Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Haloperidol.
Paroxetine	Paroxetine The risk or severity of CNS depression can be increased when Haloperidol is combined with Paroxetine.
Tolcapone	Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Haloperidol.
Citalopram	Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Haloperidol.
Capecitabine	Capecitabine The metabolism of Haloperidol can be decreased when combined with Capecitabine.
Efavirenz	Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Haloperidol.
Abacavir	Abacavir Haloperidol may decrease the excretion rate of Abacavir which could result in a higher serum level.
Sildenafil	Sildenafil The serum concentration of Haloperidol can be increased when it is combined with Sildenafil.
Pioglitazone	Pioglitazone The serum concentration of Pioglitazone can be increased when it is combined with Haloperidol.
Celecoxib	Celecoxib The serum concentration of Haloperidol can be increased when it is combined with Celecoxib.
Rosiglitazone	Rosiglitazone The serum concentration of Rosiglitazone can be increased when it is combined with Haloperidol.
Tolterodine	Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Haloperidol.
Thalidomide	Thalidomide Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir	Oseltamivir Oseltamivir may decrease the excretion rate of Haloperidol which could result in a higher serum level.
Balsalazide	Balsalazide The therapeutic efficacy of Haloperidol can be increased when used in combination with Balsalazide.
Nateglinide	Nateglinide The serum concentration of Nateglinide can be increased when it is combined with Haloperidol.
Galantamine	Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Haloperidol.
Levetiracetam	Levetiracetam The risk or severity of CNS depression can be increased when Haloperidol is combined with Levetiracetam.
Rabeprazole	Rabeprazole The serum concentration of Rabeprazole can be increased when it is combined with Haloperidol.
Terbinafine	Terbinafine The serum concentration of Haloperidol can be increased when it is combined with Terbinafine.